Who Paid My Doc
Elena Massarotti
Rheumatology Boston, MA Medical Doctor
NPI 1104980762 CMS profile 277601
75 Francis St, Division Of Rheumatology, Boston, MA 02115
General payments
$24,310
Research payments
$15,162
Ownership & investment interest
$0
Research they led as principal investigator
$31,752
Through program year 2025, Elena Massarotti of Boston, MA is reported in the CMS Open Payments database as having received $24,310 across 13 general payments and $15,162 in research payments paid to them. Separately, studies naming them as principal investigator received $31,752 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 88th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $5,535 | 4 | |
| 2024 | Research | $2,500 | 2 | |
| 2023 | General | $4,985 | 2 | |
| 2023 | Research | $6,375 | 5 | |
| 2022 | Research | $2,125 | 2 | |
| 2021 | General | $11,878 | 4 | |
| 2020 | General | $1,913 | 3 | |
| 2019 | Research | $4,162 | 4 |
Beside peers
- Elena Massarotti
- Rheumatology median
- Middle half of Rheumatology
- National median
In program year 2025, general payments to Elena Massarotti were reported at $5,535. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.
Show as a table
| Year | Elena Massarotti | Rheumatology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $744 | $153–$2,687 | $163 |
| 2020 | $1,913 | $462 | $98–$2,027 | $114 |
| 2021 | $11,878 | $531 | $101–$2,153 | $132 |
| 2022 | $0 | $627 | $125–$2,303 | $149 |
| 2023 | $4,985 | $741 | $145–$2,524 | $160 |
| 2024 | $0 | $830 | $166–$2,660 | $164 |
| 2025 | $5,535 | $903 | $171–$2,775 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 39 drugsPart D claims
1,764
Drug cost
$2,920,537
Branded share of claims
41.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Humira(Cf) Pen Adalimumab | Brand | 91 | $749,891 | |
| Enbrel Sureclick Etanercept | Brand | 74 | $544,702 | |
| Enbrel Etanercept | Brand | 41 | $266,405 | |
| Orencia Clickject Abatacept | Brand | 28 | $211,830 | |
| Xeljanz Xr Tofacitinib Citrate | Brand | 36 | $202,923 | |
| Xeljanz Tofacitinib Citrate | Brand | 25 | $193,582 | |
| Actemra Tocilizumab | Brand | 39 | $182,110 | |
| Orencia Abatacept | Brand | 24 | $132,689 | |
| Rinvoq Upadacitinib | Brand | 21 | $127,757 | |
| Humira(Cf) Adalimumab | Brand | 15 | $98,062 |
The 10 drugs with the highest cost, of 39 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 15 billing codesPaid by Medicare
$54,225
Medicare patients
381
Services billed
745
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 64% | |
| Osteoporosis | 33% | |
| Depression | 27% | |
| Ischemic heart disease | 24% | |
| Diabetes | 23% | |
| Chronic kidney disease | 23% | |
| Cancer | 17% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
26 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Rheumatology in Massachusetts
Related records
Rheumatology in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Rheumatology
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.